express
specifi
cell
tissu
organ
highli
complex
outnumb
mani
smaller
peptid
gener
fulllength
protein
proteolyt
cleavag
largest
fraction
peptidom
peptid
present
specif
cell
tissu
organ
system
compris
peptid
fragment
gener
proteolysi
larger
precursor
molecul
small
fraction
peptidom
function
character
owe
enorm
complex
lack
broadli
applic
method
enabl
unbias
analysi
mani
year
peptidom
commonli
regard
biolog
trash
howev
recent
recogn
express
activ
human
proteas
gener
peptid
alter
patholog
condit
furthermor
accumul
evid
suggest
cleavag
product
larger
precursor
protein
exert
specif
sometim
highli
unexpect
activ
human
pathogen
thu
human
peptidom
rich
sourc
diseasespecif
biomark
long
known
human
mammalian
speci
evolv
variou
antimicrobi
peptid
first
line
defenc
virus
bacteria
fungi
although
role
antimicrobi
peptid
defensin
cathelicidin
innat
immun
immun
modul
inflamm
wellestablish
seem
highli
like
mani
import
peptid
immun
modul
effector
human
bodi
remain
identifi
thousand
antimicrobi
peptid
isol
variou
natur
sourc
exampl
bacteria
fungi
plant
anim
furthermor
sever
inhibitor
bacteri
infect
isol
human
immun
cell
exampl
skin
exampl
saliva
exampl
histatin
nasal
secret
exam
ple
lysozym
semin
plasma
exampl
cathelicidin
sweat
exam
ple
dermicidin
variou
type
antimicrobi
peptid
possibl
clinic
applic
topic
sever
recent
review
innov
articl
discuss
discoveri
novel
antimicrobi
peptid
systemat
screen
highli
complex
peptid
librari
deriv
human
bodili
fluid
tissu
particular
focu
isol
endogen
agent
affect
infect
unexpect
mechan
may
implic
beyond
hivaid
furthermor
present
advantag
disadvantag
strategi
final
discuss
endogen
peptid
isol
human
peptidom
optim
therapeut
basic
research
applic
highlight
futur
direct
challeng
humanderiv
peptid
librari
peptid
librari
gener
human
bodili
fluid
tissu
blood
lymphoid
tissu
contain
essenti
peptid
small
protein
respect
sourc
final
process
physiolog
relev
form
thu
excel
sourc
identif
asyetunknown
bioactiv
peptid
clinic
approv
drug
small
molecul
compound
molecular
weight
much
less
kda
small
size
one
requir
uptak
gastrointestin
tract
thu
oral
applic
contrast
larg
protein
drug
antibodi
molecular
weight
kda
need
administ
parenter
size
peptid
usual
amino
acid
length
two
drug
class
although
strict
demarc
antimicrobi
molecul
found
three
size
class
includ
small
molecul
penicillin
kda
glycopeptid
vancomycin
kda
larg
rabiesspecif
immunoglobulin
kda
exampl
clinic
approv
antimicrobi
peptid
antibiot
polymyxin
b
polymyxin
e
also
known
colistin
antivir
agent
owe
increas
resist
microorgan
convent
antibiot
current
grow
interest
develop
antimicrobi
peptid
clinic
applic
sever
candid
clinic
trial
abstract
almost
human
protein
subject
proteolyt
degrad
produc
broad
rang
peptid
highli
specif
sometim
unexpect
function
peptid
librari
gener
human
bodili
fluid
tissu
rich
mostli
unexplor
sourc
bioactiv
compound
could
use
develop
antimicrobi
immunomodulatori
therapeut
agent
innov
articl
describ
discoveri
optim
applic
endogen
bioactiv
peptid
humanderiv
peptid
librari
particular
focu
isol
endogen
inhibitor
promot
infect
develop
antimicrobi
peptid
databas
see
inform
provid
overview
bioactiv
antibacteri
antivir
peptid
isol
natur
sourc
peptid
drug
may
less
toxic
less
like
caus
allerg
inactiv
immun
respons
smallmolecul
protein
drug
particularli
deriv
human
sourc
howev
isol
individu
bioactiv
peptid
highli
complex
human
bodili
fluid
tissu
challeng
task
gener
peptid
librari
human
haemofiltr
human
tissu
bodili
fluid
usual
avail
limit
quantiti
standard
method
purifi
bioactiv
agent
larg
number
highli
divers
peptid
protein
contain
tissu
fluid
mostli
unavail
larg
quantiti
start
materi
advantag
technic
experiment
standpoint
one
abund
sourc
human
peptid
haemo
filtrat
wast
product
dialysi
contain
essenti
blood
compon
molecular
weight
less
kda
box
avail
patient
chronic
renal
failur
quantiti
thousand
litr
combin
ultrafiltr
follow
cationexchang
separ
reversephas
chromatographi
enabl
standard
separ
concentr
peptid
small
protein
present
haemofiltr
fraction
analysi
fraction
requir
highthroughput
methodolog
facil
requir
test
librari
often
compris
hundr
thousand
compound
exampl
specif
assay
test
inhibit
particular
pathogen
modul
specif
cellular
function
induct
select
immun
factor
use
identifi
purifi
activ
agent
present
fraction
peptid
librari
use
sourc
discoveri
novel
bioactiv
agent
repres
enorm
structur
function
divers
human
peptidom
peptid
present
final
process
thu
bioactiv
form
notabl
haemofiltr
contain
endocrin
peptid
also
peptid
function
paracrin
autocrin
manner
small
fraction
peptid
releas
extracellular
space
found
blood
thu
haemofiltratederiv
peptid
librari
contain
essenti
entir
circul
blood
peptidom
lyophil
bioactiv
highli
concentr
form
howev
addit
peptid
natur
exist
human
bodi
librari
may
also
contain
proteolyt
cleavag
product
specif
aris
accumul
collect
storag
bodi
fluid
natur
review
microbiolog
haemofiltr
carri
remov
uraem
toxin
blood
patient
renal
failur
process
blood
filter
membran
molecular
weight
cutoff
kda
peptid
small
protein
filter
without
restrict
therefor
present
concentr
correspond
found
blood
plasma
wherea
larger
protein
cell
cross
membran
owe
size
return
patient
see
figur
owe
remov
larg
abund
protein
serum
albumin
total
concentr
protein
haemofiltr
reduc
compar
entir
plasma
protein
content
remain
peptid
small
protein
includ
key
modul
effector
innat
adapt
immun
respons
cytokin
chemokin
proteas
proteas
inhibitor
hormon
ribonucleas
defensin
well
mani
unknown
compound
thu
haemofiltr
wast
product
obtain
nephrolog
clinic
excel
sourc
bioactiv
peptid
small
protein
circul
bloodstream
standard
largescal
method
separ
peptid
litr
haemofiltr
develop
involv
twostep
procedur
cationexchang
separ
follow
reversephas
chromatographi
see
figur
techniqu
use
separ
purifi
peptid
protein
basi
size
charg
hydrophob
charact
respect
first
step
haemofiltr
dilut
acidifi
appli
larg
cationexchang
column
stepwis
batch
elut
bound
peptid
carri
use
seven
eight
buffer
increas
ph
result
phpool
fraction
subsequ
separ
reversephas
chromatographi
differ
peptidecontain
fraction
concentr
lyophyl
final
product
haemofiltratederiv
peptid
librari
compris
dri
fraction
repres
essenti
entir
blood
peptidom
highli
concentr
saltfre
bioactiv
form
although
fraction
still
contain
thousand
differ
peptid
complex
greatli
reduc
compar
human
plasma
furthermor
aliquot
peptid
mixtur
test
bioassay
concentr
sever
order
magnitud
higher
origin
present
human
blood
thu
peptid
librari
facilit
identif
isol
bioactiv
molecul
circul
blood
peptidom
tissu
nonetheless
peptid
librari
excel
sourc
identif
endogen
bioactiv
peptid
larg
quantiti
start
materi
advantag
alway
obligatori
identif
novel
endogen
bioactiv
peptid
fact
mani
peptid
protein
becom
activ
exert
respect
function
specif
compart
site
infect
andor
inflamm
exampl
saliva
genit
fluid
milk
sweat
contain
particularli
larg
number
antimicrobi
peptid
isol
agent
circul
bloodstream
import
gener
peptid
librari
sourc
haemofiltr
principl
produc
tissu
bodili
fluid
use
ultrafiltr
cation
exchang
follow
reversephas
chromatographi
peptid
librari
gener
human
plasma
milk
placenta
sweat
semin
plasma
saliva
jm
ls
wgf
fk
unpublish
observ
antimicrobi
peptid
isol
librari
list
tabl
human
peptid
affect
infect
clinic
use
antiretrovir
drug
small
molecul
select
specif
target
inhibit
viral
protein
essenti
replic
enfuvirtid
also
known
trimeri
current
licens
peptid
antiretrovir
drug
enfuvirtid
deriv
region
viral
transmembran
glycoprotein
known
heptad
repeat
mimick
competit
bind
anoth
region
known
enfuvirtid
prevent
interact
thu
prevent
conform
chang
requir
virion
fusion
host
cell
although
protein
human
sourc
enfuvirtid
provid
exampl
feasibl
develop
peptid
antiretrovir
agent
addit
chemokin
cxcchemokin
ligand
also
known
ccchemokin
ligand
also
known
also
known
also
known
rant
bind
g
proteincoupl
receptor
gpcr
cxcchemokin
receptor
ccchemokin
receptor
respect
prevent
infect
strain
use
receptor
viral
entri
fact
inhibitori
activ
crucial
discoveri
main
coreceptor
entri
modifi
deriv
extrem
potent
inhibitor
strain
vitro
low
effici
vivo
sever
intracellular
host
protein
inhibit
replic
differ
step
viral
life
cycl
known
restrict
factor
recent
discov
seem
highli
like
addit
antiretro
viral
peptid
andor
protein
remain
discov
inhibitor
initi
screen
haemofiltratederiv
peptid
librari
ligand
identifi
natur
occur
truncat
form
abund
human
chemokin
potent
agonist
receptor
inhibit
infect
strain
notabl
chemokin
specif
fragment
also
inhibit
ref
import
pathogen
plasmodium
falciparum
screen
haemofiltratederiv
peptid
fraction
identifi
anoth
inhibitor
cproxim
subfrag
serin
proteas
design
virusinhibitori
peptid
virip
peptid
purifi
multipl
round
peptid
separ
antivir
screen
fig
virip
specif
interact
viral
fusion
peptid
locat
amino
terminu
transmembran
domain
region
distinct
region
target
enfuvirtid
virip
block
entri
step
membran
fusion
penetr
insert
viral
fusion
peptid
host
cell
membran
fig
novel
unexpect
mechan
fusion
peptid
becom
access
viral
entri
process
conform
chang
ref
thu
assum
anchor
step
inhibit
remark
approach
identifi
wellknown
ligand
instead
identifi
novel
agonist
suggest
relev
peptid
ligand
gpcr
target
mani
modern
drug
remain
discov
analys
show
cproxim
fragment
prostat
acid
phosphatas
pap
abund
enzym
semen
selfassembl
cation
amyloid
fibril
fibril
known
semenderiv
enhanc
viru
infect
sevi
increas
infecti
viru
titr
cell
cultur
sever
order
magnitud
facilit
viru
infect
nonhuman
primat
model
exposur
low
viral
dose
approxim
vivo
situat
viru
attach
usual
ineffect
densiti
viral
envelop
glycoprotein
virion
receptor
target
cell
low
surfac
viral
cellular
membran
neg
charg
usual
repel
sevi
fibril
format
posit
surfac
charg
crucial
increas
infect
suggest
sevi
promot
attach
viru
target
cell
neutral
repuls
neg
charg
viral
cellular
membran
fig
interestingli
followup
studi
show
nproxim
fragment
pap
well
peptid
deriv
semenogelin
semenogelin
abund
protein
semen
also
form
amyloid
fibril
increas
infect
endogen
amyloid
fibril
recent
detect
fresh
nonmodifi
ejacul
structur
character
notabl
level
correl
effici
semenmedi
promot
infect
vitro
thu
semen
main
vector
transmiss
contain
amyloid
fibril
boost
viral
infect
therefor
novel
target
reduc
risk
sexual
transmiss
fact
sever
agent
block
format
infectionpromot
activ
semenderiv
fibril
report
amyloid
may
also
exploit
pathogen
recent
data
show
semen
amyloid
also
increas
cytomegaloviru
cmv
infect
semen
first
bodili
fluid
identifi
natur
contain
amyloid
fibril
nondiseas
state
physiolog
role
semin
amyloid
healthi
individu
remain
defin
howev
tempt
specul
might
involv
innat
immun
fertil
optim
develop
virip
activ
lower
micromolar
rang
concentr
may
well
physiolog
relev
readili
achiev
proteolyt
cleavag
highli
abund
precursor
howev
concentr
suboptim
therapeut
applic
usual
requir
activ
nanomolar
rang
specif
modif
natur
inhibitor
increas
antivir
activ
two
order
magnitud
chemic
modif
n
terminu
render
peptid
resist
degrad
therebi
strongli
increas
antiretrovir
potenc
case
virip
introduct
amino
acid
alter
stabil
activ
conform
peptid
increas
hydrophob
interact
fusion
peptid
greatli
increas
antivir
figur
use
humanderiv
peptid
librari
isol
bioactiv
peptid
schemat
outlin
gener
strategi
isol
unknown
antivir
peptid
human
peptid
librari
isol
inhibitor
virusinhibitori
peptid
virip
shown
exampl
ph
pool
obtain
use
cation
exchang
subject
reversephas
chromatographi
result
fraction
assay
antivir
activ
exampl
effect
replic
activ
fraction
indic
red
purifi
multipl
round
chromatographi
cycl
separ
screen
reduc
complex
peptid
sampl
purifi
bioactiv
agent
identifi
mass
spectrometri
analysi
peptid
sequenc
virip
shown
leaipmsippevkfnkpfvf
fragment
serin
proteas
identifi
peptid
function
character
optim
clinic
develop
potenc
notabl
shortterm
monotherapi
one
optim
deriv
known
well
toler
reduc
plasma
viral
load
treatmentna
patient
ref
provid
proofofconcept
natur
occur
antivir
peptid
optim
therapeut
applic
owe
mode
applic
inject
high
cost
involv
peptid
synthesi
virip
deriv
yet
competit
mani
highli
effect
oral
avail
smallmolecul
drug
avail
treatment
hivaid
sever
strategi
underway
increas
efficaci
applic
virip
deriv
includ
packag
nanoparticl
improv
deliveri
stabil
well
structurebas
optim
semenderiv
amyloid
fibril
also
develop
applic
boost
infect
could
use
improv
retrovir
gene
deliveri
inde
sevi
increas
effici
retrovir
gene
transfer
although
moder
variabl
effici
basi
find
broader
screen
carri
amyloidogen
peptid
function
promot
retrovir
transduct
studi
led
develop
synthet
peptid
known
efc
protransduzin
phari
biotec
gmbh
instantan
selfassembl
nanofibril
promot
retrovir
gene
transfer
effici
semenderiv
fibril
furthermor
efc
captur
virion
thu
enabl
retrovir
particl
concentr
convent
lowspe
centrifug
instead
labori
ultracentrifug
far
use
viru
concentr
develop
pave
way
new
class
promot
retrovir
gene
transfer
basic
research
clinic
applic
remark
singl
assay
system
inhibit
infect
led
discoveri
three
novel
endogen
agent
affect
entri
distinct
mechan
fig
discuss
peptid
structur
function
distinct
posit
charg
amphipath
antimicrobi
peptid
might
implic
addit
hivaid
innat
adapt
immun
well
sperm
function
fertil
also
strike
newli
identifi
modul
infect
gener
highli
abund
precursor
protein
pap
semenogelin
proteas
gener
bioactiv
peptid
remain
fulli
defin
howev
least
case
proteas
releas
immun
cell
induc
activ
inflamm
exampl
virip
gener
matrix
metalloproteinas
gener
serin
proteas
furthermor
endogen
peptid
interact
respect
target
highli
specif
manner
subtl
structur
chang
n
terminu
exampl
remov
ad
singl
amino
acid
residu
disrupt
function
activ
thu
tempt
specul
cleavag
abund
precursor
may
common
fast
effect
mean
gener
immunomodul
antimicrobi
peptid
locat
time
actual
need
like
peptid
role
variou
biolog
process
moreov
rapid
gener
specif
effector
proteolysi
abund
precursor
protein
instead
de
novo
protein
synthesi
may
particularli
advantag
innat
defenc
mechan
invad
pathogen
immedi
respons
crucial
effect
counteract
notabl
local
extracellular
acidif
activ
variou
proteas
current
emerg
key
regulatori
concept
innat
immun
antimicrobi
peptid
use
peptid
librari
human
sourc
discoveri
novel
factor
modul
infect
prime
exampl
natur
review
microbiolog
unlik
semenderiv
enhanc
agent
human
peptid
isol
haemofiltr
antivir
activ
truncat
form
abund
human
chemokin
ccchemokin
ligand
inhibit
entri
strain
bind
ccchemokin
receptor
coreceptor
humanderiv
virusinhibitori
peptid
virip
subfrag
serin
proteas
inhibitor
also
target
fusion
peptid
specif
interact
amino
terminu
transmembran
domain
block
penetr
insert
viral
fusion
peptid
enfuvirtid
synthet
peptid
deriv
region
transmembran
glycoprotein
inhibitor
bind
helic
repeat
region
region
distinct
region
target
virip
prevent
format
hairpin
structur
requir
membran
fusion
therebi
block
infect
moreov
endogen
human
glyceraldehyd
dehydrogenas
gapdh
peptid
isol
human
placent
tissu
fragment
intern
candida
albican
kill
pathogen
induc
rapid
apoptot
death
discoveri
base
limit
number
antimicrobi
screen
suggest
human
peptidom
might
yield
surpris
find
current
key
challeng
purif
identif
activ
compound
complex
peptid
mixtur
activ
fraction
gener
peptid
librari
howev
rapid
progress
made
develop
improv
methodolog
peptid
separ
analysi
exampl
stateoftheart
mass
spectrometri
method
enabl
conveni
deduct
peptid
sequenc
complex
fragment
spectra
furthermor
highli
sensit
timeofflight
tof
mass
spectromet
matrixassist
laser
desorptionionizatio
n
maldi
electrospray
ioniz
esi
alreadi
enabl
accur
mass
determin
peptid
femtomolar
concentr
combin
autom
highthroughput
sampl
handl
togeth
miniatur
liquid
chromatographi
approach
power
mass
spectrometr
technolog
greatli
facilit
identif
character
bioactiv
endogen
peptid
futur
studi
endogen
peptid
clinic
sever
disadvantag
limit
use
peptid
therapeut
agent
includ
fact
usual
oral
avail
often
unstabl
nonetheless
alreadi
use
treatment
cancer
diabet
cardiovascular
diseas
grow
interest
use
peptid
therapeut
area
particularli
antimicrobi
agent
owe
increas
number
multidrugresist
bacteria
virus
mani
antimicrobi
peptid
broadli
activ
often
target
conserv
compon
bacteri
membran
furthermor
peptid
neutral
endotoxin
difficult
pathogen
develop
resist
exampl
variant
show
reduc
sensit
virip
year
cell
cultur
passag
presenc
inhibitor
accumul
evid
also
suggest
antimicrobi
peptid
immunomodulatori
antineoplast
properti
thu
offer
prospect
treatment
inflamm
cancer
potenti
advantag
peptid
usual
easi
synthes
readili
modifi
optim
activ
specif
stabil
notabl
cost
peptid
synthes
rapidli
decreas
novel
deliveri
method
may
increas
efficaci
eventu
even
enabl
oral
applic
consequ
number
peptid
compound
enter
clinic
trial
steadili
increas
mani
candid
clinic
preclin
develop
thu
although
low
stabil
physiolog
condit
lack
oral
bioavail
still
import
challeng
strategi
optim
bioactiv
endogen
peptid
clinic
applic
seem
highli
promis
altern
may
possibl
induc
appli
proteas
gener
activ
peptid
abund
precursor
treat
infecti
inflammatori
diseas
human
peptidom
probabl
contain
mani
unknown
factor
may
key
role
antimicrobi
immun
inflammatori
process
bioactiv
peptid
identifi
genom
transcriptom
approach
detect
posttransl
modif
peptid
librari
deriv
bodili
fluid
tissu
facilit
systemat
unbias
identif
hidden
treasur
activ
may
certainli
miss
rel
weak
antimicrobi
agent
may
degrad
inactiv
sampl
process
storag
nonetheless
methodolog
seem
suitabl
identifi
potent
stabl
endogen
antimicrobi
peptid
longer
term
envis
highli
reproduc
gener
peptid
librari
multipl
sourc
combin
robust
assay
identif
factor
affect
key
pathogen
biolog
activ
also
specul
novel
power
techniqu
purif
optim
product
deliveri
endogen
peptid
greatli
facilit
futur
clinic
develop
